Agenda for October 2026 Cardiovascular Advisory Committee meeting

Matters Arising

Direct Acting Oral Anticoagulants (DOACs)

The Committee will discuss Direct Acting Oral Anticoagulants (DOACs) in preparation for a potential request for proposals (RFP).

Polypills for cardiovascular risk reduction

The Committee will discuss correspondence requesting a review of polypills for cardiovascular risk reduction. Polypills are fixed-dose combinations of two or more medicines used to treat or prevent chronic conditions such as cardiovascular disease.

Applications

Semaglutide (Branded as Wegovy) for people with established cardiovascular disease

The Committee will discuss an application for semaglutide for people with established cardiovascular disease who have a high body mass index (BMI of 27 kg/m² or greater), or moderate/severe obesity (BMI of 35 kg/m2 or greater).

Application for semaglutide(external link)

Mavacamten (Branded as Camzyos) for obstructive hypertrophic cardiomyopathy

The Committee will discuss an application for mavacamten as a second-line treatment for people with obstructive hypertrophic cardiomyopathy (HCM) whose symptoms are not adequately controlled with, or who cannot tolerate, standard treatment.

Application for mavacamten(external link)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.